CEO Pay Packages Expand in India But Ratio To Employee Earnings Hurts
Top executives at leading local and foreign drug firms in India by and large earned more in 2020-21, while differentials in CEO to median employee remuneration remained stark. With increasing scrutiny by shareholders and lawmakers, experts suggest that pharma should be more mindful of balancing “adequate” C-suite compensation and glaring inequalities.
You may also be interested in...
Duato has been involved for the last several years in growing J&J’s pharma and consumer businesses and has led the company’s COVID-19 efforts. Gorsky is stepping down due to a family health issue.
Managing directors/CEOs of foreign firms in India drew higher remuneration in 2019-20 versus the previous year and overall earnings of peers at Indian firms continued to be way higher in general. CEO-to-employee pay ratios remains stark, reaching over 550 in one case.
Industry leaders including Sanofi's ex-CEO and the chiefs of Sun, Lupin, Glenmark, Dr Reddy’s and Cipla discuss how India could leapfrog its pharma R&D efforts. Could the South Korea model or a hybrid approach including bringing back top talent bolster the country’s efforts to emerge as a global innovation hot spot?